Works from 2024
Cannabis and cannabinoids in adults with cancer: ASCO Guideline, Ilana M. Braun, Kari Bohlke, Donald I. Abrams, et al. (Article)
Real-world outcomes with immuno-oncology therapies in advanced melanoma: Final results of the OPTIMIzE registry study, John M. Kirkwood, Lisa A. Kottschade, Robert R. McWilliams, et al. (Article)
Systemic therapy for breast cancer, Sigrun Hallmeyer, Rubina Qamar, and Corey J. Shamah (Book Chapter)
Works from 2023
A case of recurrent multiple myeloma as testicular plasmacytoma without systemic disease, Krishna Doshi, Sabree Abedrabo, Jacob Bitran, et al. (Article)
A case of TAFRO syndrome with DIC and neurologic and cardiac involvement, Lindsay N. Moy, Mauli Patel, Josiah Eschbach, et al. (Article)
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing, Sigrun Hallmeyer, Michael A. Thompson, Veronica Fitzpatrick, et al. (Article)
Immunoglobulin Light Chain (AL) Amyloidosis Preceding Marginal Zone Lymphoma: A Case Report, Krishna Doshi, Jacob Bitran, Brian Adley, and Nahren Asado (Poster)
Pembrolizumab for patients with non-Hodgkin lymphoma: Phase 1b KEYNOTE-013 study, John Kuruvilla, Philippe Armand, Mehdi Hamadani, et al. (Article)
ZUMA-24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma given outpatient with corticosteroids, L Leslie, M Tees, Tulio E. Rodriguez, et al. (Abstract)
Works from 2022
A prospective, longitudinal evaluation of SARS-CoV-2 COVID-19 exposure, use of protective equipment and social distancing in a group of community physicians, Eli D. Ehrenpreis, Sigrun Hallmeyer, David H. Kruchko, et al. (Article)
A review of the abscopal effect in the era of immunotherapy, Edward Nabrinsky, Jason Macklis, and Jacob Bitran (Article)
Characteristics of patients with hematologic malignancies without seroconversion post-COVID19 third vaccine dosing (3V): Real-world data from large midwestern healthcare system, Sigrun Hallmeyer, Michael A. Thompson, Veronica Fitzpatrick, et al. (Abstract)
Factors associated with COVID-19 breakthrough infections in large midwestern healthcare system: Implications for vulnerable healthcare personnel, Anne Rivelli, Veronica Fitzpatrick, Kenneth Copeland, et al. (Article)
Factors associated with COVID-19 breakthrough infections in large Midwestern healthcare system: Implications for vulnerable healthcare personnel, Anne Rivelli, Veronica Fitzpatrick, Kenneth Copeland, et al. (Response or Comment)
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma, Michael L. Wang, SHINE Investigators, Leonard Klein, et al. (Article)
Identifying predictors of equitable gender representation among hematology and oncology fellowship programs, Sasirekha Pandravada, Praneet Mylavarapu, and Jacob D. Bitran (Abstract)
Immunoglobulin light chain (AL) amyloidosis Preceding marginal zone lymphoma: A case report, Krishna Doshi, Jacob Bitran, Brian Adley, et al. (Article)
Incidence of COVID-19 reinfection among Midwestern healthcare employees, Anne Rivelli, Veronica Fitzpatrick, Christopher Blair, et al. (Article)
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study, Brendan D. Curti, Jon Richards, John R. Hyngstrom, et al. (Article)
Mantle zone lymphoma with prostate gland enlargement: A case report, Krishna Doshi, Anjana Chandran, Yanxia Li, et al. (Article)
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma, Loretta J. Nastoupil, John Kuruvilla, Julio C. Chavez, et al. (Article)
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies, Michael A. Thompson, Sigrun Hallmeyer, Veronica E. Fitzpatrick, Yunqi Liao, Michael P. Mullane, Stephen C. Medlin, Kenneth Copeland, and James L. Weese (Original Research)
Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update, Andrea Eisen, Mark R. Somerfield, Melissa K. Accordino, et al. (Article)
Works from 2021
ALL-071: A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), Sharif Khan, Shahram Mori, Tulio E Rodriguez, et al. (Abstract)
An open-label, randomized, multi-center study comparing the sequence of high dose aldesleukin (interleukin-2) and ipilimumab (yervoy) in patients with metastatic melanoma, Merve Hasanov, Denái R. Milton, William H. Sharfman, et al. (Article)
Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma, Andtbacka, Brendan Curti, Gregory A Daniels, et al. (Article)
Disparities in seroprevalence of SARS-CoV-2 immunoglobulin antibodies in a large Midwestern health care system, Fitzpatrick, Anne Rivelli, Chris Blair, et al. (Article)
Incidence of COVID-19 recurrence among large cohort of healthcare employees, Fitzpatrick, Anne Rivelli, Chris Blair, et al. (Article)
Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma, Olson, Zeynep Eroglu, Bruce Brockstein, et al. (Article)
Primary central nervous system lymphoma with systemic recurrence, Sasirekha Pandravada, Phillip Knouse, and Jacob Bitran (Article)
Works from 2020
Medicare compared with private insurance for the treatment of cancer, Phillip Martinez-Knouse, Christie Hancock, Edward Nabrinsky, et al. (Abstract)
REPOCH compared with RCHOP for the treatment of diffuse large B-cell lymphoma of activated B-cell type, Phillip Martinez-Knouse, Edward Nabrinsky, Anjana Chandran, et al. (Abstract)